Enanta Pharmaceuticals, Inc. (ENTA) Reaches $62.54 After 7.00% Up Move; Chase (CCF) Has 1.05 Sentiment

January 16, 2018 - By Ellis Scott

The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a huge mover today! The stock increased 2.55% or $1.555 during the last trading session, reaching $62.535. About 111,266 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 40.91% since January 16, 2017 and is uptrending. It has outperformed by 24.21% the S&P500.The move comes after 5 months positive chart setup for the $1.20B company. It was reported on Jan, 16 by Barchart.com. We have $66.91 PT which if reached, will make NASDAQ:ENTA worth $83.72M more.

Chase Corporation manufactures and sells protective materials for various applications worldwide. The company has market cap of $1.09 billion. It operates through two divisions, Industrial Materials and Construction Materials. It has a 27.59 P/E ratio. The Industrial Materials segment offers insulating and conducting materials; laminated film foils, composite strength elements, anti-static packaging tapes, and pulling tapes; moisture protective coatings; laminated durable papers, including laminated paper; detection and cover tapes; flexible, rigid, and semi-rigid fiber optic strength elements; polymeric microspheres; and water polyurethane dispersions.

Minerva Advisors Llc holds 14.62% of its portfolio in Chase Corporation for 248,308 shares. Wilen Investment Management Corp. owns 135,924 shares or 8.94% of their US portfolio. Moreover, Fca Corp Tx has 2.6% invested in the company for 56,569 shares. The Massachusetts-based Choate Investment Advisors has invested 1.42% in the stock. Teton Advisors Inc., a New York-based fund reported 95,133 shares.

Since January 1, 0001, it had 0 insider buys, and 5 sales for $43,035 activity.

The stock increased 0.22% or $0.25 during the last trading session, reaching $116.45. About 7,168 shares traded. Chase Corporation (CCF) has risen 81.05% since January 16, 2017 and is uptrending. It has outperformed by 64.35% the S&P500.

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Enanta Pharmaceuticals Inc had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Hold” rating by Robert W. Baird on Friday, September 15. The rating was downgraded by RBC Capital Markets on Tuesday, January 2 to “Sector Perform”. JMP Securities downgraded the shares of ENTA in report on Thursday, April 28 to “Market Perform” rating. On Friday, October 20 the stock rating was maintained by RBC Capital Markets with “Buy”. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has “Neutral” rating given on Tuesday, August 8 by Robert W. Baird. The company was maintained on Tuesday, August 9 by JP Morgan. The firm has “Hold” rating by Robert W. Baird given on Monday, November 20. TheStreet downgraded the stock to “Buy” rating in Saturday, August 8 report. RBC Capital Markets maintained the stock with “Buy” rating in Monday, November 20 report. Zacks downgraded Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Friday, August 7 to “Buy” rating.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.20 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 68.72 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Investors sentiment increased to 1.6 in 2017 Q3. Its up 0.75, from 0.85 in 2017Q2. It is positive, as 9 investors sold Enanta Pharmaceuticals, Inc. shares while 31 reduced holdings. 16 funds opened positions while 48 raised stakes. 12.10 million shares or 2.87% more from 11.77 million shares in 2017Q2 were reported. Texas Permanent School Fund stated it has 10,423 shares. Credit Suisse Ag owns 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 31,994 shares. Armistice Cap Limited reported 108,000 shares. Arizona State Retirement Systems invested 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Prudential has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Aqr Management Ltd Liability Company stated it has 0.01% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Pacad Ltd holds 1,700 shares or 0.02% of its portfolio. Price T Rowe Associates Md has invested 0% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Thrivent For Lutherans stated it has 8,730 shares. Manufacturers Life Insurance The holds 0% or 11,974 shares in its portfolio. Pnc Financial Inc reported 170 shares or 0% of all its holdings. Alps Advsrs reported 18,747 shares or 0.01% of all its holdings. Citigroup reported 0% stake. Envestnet Asset Mngmt reported 2 shares stake. Proshare Limited Liability Company invested in 0.01% or 12,098 shares.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on February, 14. They expect $0.04 earnings per share, up 115.38% or $0.30 from last year’s $-0.26 per share. ENTA’s profit will be $765,012 for 390.84 P/E if the $0.04 EPS becomes a reality. After $1.86 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -97.85% negative EPS growth.